Clinical Trial

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

Recruiting Phase 2

Summary

Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with \[angiotensin receptor/neprilysin inhibitor \[ARNI\] + sodium-glucose cotransporter 2 inhibitor \[SGLTi\] + mineralocorticoid receptor antagonist \[MRA\]) or with individualized medical therapy \[SGLTi + renin-angiotensin system inhibitor \[RASi\] \[angiotensin receptor blocker \[ARB\] or angiotensin-converting enzyme inhibitor \[ACE-I\]), and will be treated for 52 weeks

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2024-10-21; most recent amendment 2026-04-21.

Status change: Not Yet Recruiting → Recruiting 2026-04-21

Trial Details

NCT Number	NCT06655480
Lead Sponsor	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Collaborators: Lomonosov Moscow State University Medical Center
Conditions	HFpEF, LVDD, Myocardial Fibrosis
Enrollment	50 participants
Start Date	2025-03-18
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-24